Moderna, Inc. $MRNA is TB Alternative Assets Ltd.'s 8th Largest Position

Key Points

• TB Alternative Assets Ltd. increased its stake in Moderna, Inc. by 93.3% in Q2, making it the firm's 8th largest holding.
• Moderna reported a revenue of $142 million for the last quarter, surpassing estimates, but still saw a 41.1% decline in revenue year-over-year.
• Analyst ratings for Moderna show a consensus rating of "Hold" with a target price of $41.81.

TB Alternative Assets Ltd. boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 93.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,260,953 shares of the company's stock after acquiring an additional 608,580 shares during the quarter. Moderna accounts for 6.4% of TB Alternative Assets Ltd.'s portfolio, making the stock its 8th biggest holding. TB Alternative Assets Ltd. owned about 0.33% of Moderna worth $34,790,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Invesco Ltd. lifted its holdings in shares of Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock worth $166,801,000 after buying an additional 877,162 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Moderna by 0.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company's stock worth $101,982,000 after buying an additional 11,270 shares during the period. Northern Trust Corp lifted its holdings in shares of Moderna by 5.4% in the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company's stock worth $88,441,000 after buying an additional 160,572 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock worth $74,557,000 after buying an additional 285,662 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Moderna by 1.8% in the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock worth $54,382,000 after buying an additional 34,034 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

MRNA has been the subject of several research reports. William Blair reiterated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Leerink Partners reduced their target price on Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research report on Friday, August 22nd. Evercore ISI set a $32.00 target price on Moderna in a research report on Friday, August 1st. Morgan Stanley reaffirmed an "equal weight" rating and set a $32.00 target price on shares of Moderna in a research report on Friday, August 1st. Finally, Bank of America reduced their target price on Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a research report on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, Moderna has a consensus rating of "Hold" and a consensus target price of $41.81.

Moderna Stock Up 0.3%

Shares of MRNA opened at $25.88 on Thursday. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $67.96. The company has a market capitalization of $10.07 billion, a price-to-earnings ratio of -3.44 and a beta of 1.93. The stock's 50-day moving average price is $27.20 and its 200-day moving average price is $27.80.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company's revenue was down 41.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.